In its July meeting, the EMA’s human medicines committee recommended 14 medicines and held a negative opinion for authorising lecanemab to treat Alzheimer’s disease.
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
Become a member to continue reading
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation
